NKTR Nektar Therapeutics - Common Stock
$72,34
Kurs · Aug 18, 2026
Fundamentaldaten per Aug 14, 2026
52W-Spanne
$25–$109
56% of range
Analystenbewertung
BUY
17 analysts
Kursziel
$153
+112% upside
P/E (TTM)
-10.8
ROE
-500.1%
Nettogewinnmarge
-297.1%
Über Nektar Therapeutics - Common Stock Unternehmensübersicht von Wikipedia
Nektar Therapeutics Inc. ist ein US-amerikanisches Pharmaunternehmen mit Sitz in San Francisco, Kalifornien, Vereinigte Staaten, das im Jahre 1990 gegründet wurde. Das Unternehmen entdeckt und entwickelt Medikamente in Bereichen mit hohem medizinischem Bedarf. Die Forschungs- und Entwicklungspipeline des Unternehmens für neue Prüfpräparate umfasst Behandlungen für Krebs und Autoimmunerkrankungen. Es nutzt seine Chemieplattform, um neue Medikamentenkandidaten zu entdecken und zu entwerfen. Diese Wirkstoffkandidaten nutzen ihre Technologieplattformen für Polymerkonjugate, die die Entwicklung neuer molekularer Einheiten ermöglichen sollen, die auf bekannte Wirkmechanismen abzielen. Die Programme umfassen Immunonkologie (I-O), Immunologie und Onkologie mit dem in der Entwicklung befindlichen Medikament ONZEALD. Es werden Medikamente entwickelt, die die Aktivität wichtiger Immunzellen wie zytotoxischer T-Zellen und Natural Killer (NK) -Zellen direkt oder indirekt modulieren sollen, um ihre Anzahl zu erhöhen und ihre Funktion zur Erkennung und zum Angriff auf Krebszellen zu verbessern.
Mehr lesen
Nektar Therapeutics Inc. ist ein US-amerikanisches Pharmaunternehmen mit Sitz in San Francisco, Kalifornien, Vereinigte Staaten, das im Jahre 1990 gegründet wurde.
Das Unternehmen entdeckt und entwickelt Medikamente in Bereichen mit hohem medizinischem Bedarf. Die Forschungs- und Entwicklungspipeline des Unternehmens für neue Prüfpräparate umfasst Behandlungen für Krebs und Autoimmunerkrankungen. Es nutzt seine Chemieplattform, um neue Medikamentenkandidaten zu entdecken und zu entwerfen. Diese Wirkstoffkandidaten nutzen ihre Technologieplattformen für Polymerkonjugate, die die Entwicklung neuer molekularer Einheiten ermöglichen sollen, die auf bekannte Wirkmechanismen abzielen. Die Programme umfassen Immunonkologie (I-O), Immunologie und Onkologie mit dem in der Entwicklung befindlichen Medikament ONZEALD (ein Topoisomerase I-Inhibitor). Es werden Medikamente entwickelt, die die Aktivität wichtiger Immunzellen wie zytotoxischer T-Zellen und Natural Killer (NK) -Zellen direkt oder indirekt modulieren sollen, um ihre Anzahl zu erhöhen und ihre Funktion zur Erkennung und zum Angriff auf Krebszellen zu verbessern.
Nektar Therapeutics ist ein Technologielieferant für eine Reihe von Pharmaunternehmen, darunter Takeda Pharmaceutical, AstraZeneca, UCB, Hoffmann-La Roche, Bausch Health, Pfizer, Amgen, Halozyme Therapeutics, Bristol-Myers Squibb, Baxalta, Eli Lilly und Merck KGaA.
Das Unternehmen entwickelte das weltweit erste inhalierbare nicht injizierbare Insulin, Exubera, das vom Wall Street Journal für seinen technologischen Durchbruch mit Bronze ausgezeichnet wurde.
== Einzelnachweise ==
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
NKTR Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$72.34
Marktkapitalisierung
$2.13B
P/E (TTM)
-10.8
EPS (TTM)
$-9.73
Umsatz (TTM)
$55M
Dividendenrendite
—
ROE
-500.1%
Verschuldungsgrad
—
52W-Spanne
$25 – $109
NKTR Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$55M
2016-12-31
→
2025-12-31
EPS
$-9.73
2016-12-31
→
2025-12-31
Freier Cashflow
$-209M
2016-12-31
→
2025-12-31
Margen
-297.1%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
NKTR
Peer-Median
P/E (TTM)
-10.8
29.4
P/S (TTM) (K/V (TTM))
38.6
4.9
P/B (K/B)
23.7
6.5
Price / FCF (Kurs / FCF)
-10.2
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
NKTR
Peer-Median
Operating Margin (Betriebsgewinnmarge)
-253.7%
—
Net Profit Margin (Nettogewinnmarge)
-297.1%
-9.0%
ROA
-56.2%
-8.2%
ROE
-500.1%
-19.4%
ROIC
-155.8%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
NKTR
Peer-Median
Current Ratio (Liquiditätsgrad)
5.0
3.6
Quick Ratio
0.3
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
NKTR
Peer-Median
Revenue YoY (Umsatz YoY)
-43.9%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
-15.7%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
-18.4%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
NKTR
Peer-Median
NKTR Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
17 Analysten
- Starker Kauf 7 41,2%
- Kauf 8 47,1%
- Halten 2 11,8%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
9 Analysten · 2026-08-16
Median
$151.00
← Unter allen Zielen
$72.34
Tief
$80.00
Hoch
$192.00
Median-Ziel
$151.00
+108,7%
Mittelwert-Ziel
$153.22
+111,8%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.21%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-1.23 | $-2.02 | 0.79% |
| 31. März 2026 | $-1.82 | $-1.63 | -0.19% |
| 31. Dezember 2025 | $-1.78 | $-2.52 | 0.74% |
| 30. September 2025 | $-1.87 | $-2.74 | 0.87% |
| 30. Juni 2025 | $-2.95 | $-3.10 | 0.15% |
| 31. März 2025 | $-3.60 | $-2.51 | -1.1% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| NKTR | $862M | -4.3 | -43.9% | -297.1% | -500.1% | — |
| ALMS | — | -3.4 | — | -1011.8% | -61.9% | — |
| TARS | $3.48B | -51.5 | 146.7% | -14.7% | -19.7% | — |
| SUPN | $2.86B | -73.1 | 8.6% | -5.4% | -3.6% | — |
| ATAI | $223M | -1.4 | -1.9% | -48464.0% | -83.1% | — |
| TRVI | $1.61B | -39.1 | — | — | -22.4% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| AMLX | $1.33B | -7.9 | -77.1% | — | -61.2% | — |
| PBH | $3.33B | 15.2 | -4.3% | 17.5% | 10.2% | 54.7% |
| RAPP | $1.45B | -10.6 | — | — | -29.8% | — |
| OCUL | $2.62B | -8.5 | -18.5% | -511.9% | -55.4% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Cost of Revenue | $0 | $31M | $34M | $22M | $25M | $19M | $21M | $24M | $31M | $30M | $34M | $29M | |
| R&D Expense | $117M | $121M | $114M | $218M | $400M | $409M | $435M | $400M | $268M | $204M | $183M | $148M | |
| SG&A Expense | $69M | $77M | $77M | $92M | $123M | $105M | $99M | $81M | $52M | $44M | $43M | $41M | |
| Operating Expenses | $195M | $204M | $354M | $468M | $548M | $578M | $555M | $505M | $367M | $278M | $260M | $217M | |
| Operating Income | $-140M | $-105M | $-264M | $-376M | $-446M | $-425M | $-440M | $688M | $-60M | $-113M | $-29M | $-16M | |
| Interest Expense | · | · | · | $0 | $0 | $7M | $21M | $22M | $22M | $22M | $18M | $18M | |
| Interest Income | $10M | $14M | $19M | $7M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $361.0K | $-390.0K | $-6M | $-116.0K | $-162.0K | $18M | $46M | $38M | $5M | $2M | $2M | $814.0K | |
| Pretax Income | $-164M | $-119M | $-276M | $-365M | $-523M | $-444M | $-440M | $683M | $-96M | $-153M | $-81M | $-54M | |
| Income Tax | $-138.0K | $-239.0K | $-200.0K | $3M | $557.0K | $493.0K | $613.0K | $1M | $616.0K | $876.0K | $506.0K | $-512.0K | |
| Net Income | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| EPS (Basic) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $4.02 | $-0.62 | $-1.10 | · | · | |
| EPS (Diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | · | · | |
| Shares (Basic) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 169,600,000 | 155,953,000 | 139,596,000 | · | · | |
| Shares (Diluted) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 180,119,000 | 155,953,000 | 139,596,000 | · | · | |
| EBITDA | $-140M | $-101M | $-257M | $-364M | $-433M | $-413M | $-429M | $697M | $-47M | $-113M | $-29M | · |
Bilanz 24
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $44M | $35M | $88M | $25M | $199M | $96M | $195M | $5M | $60M | $56M | $12M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $291M | $329M | $253M | $225M | |
| Receivables | · | $0 | $1M | $6M | $22M | $39M | $37M | $43M | $5M | $16M | $20M | $4M | |
| Inventory | $0 | $0 | $16M | $19M | $16M | $15M | $13M | $11M | $11M | $11M | $11M | $13M | |
| Other Current Assets | $21M | $6M | $10M | $16M | $23M | $22M | $15M | $21M | $8M | $10M | $10M | $9M | |
| Current Assets | $266M | $261M | $331M | $546M | $796M | $1.14B | $1.42B | $1.44B | $327M | $426M | $350M | $288M | |
| PP&E (Net) | $2M | $3M | $19M | $32M | $61M | $60M | $66M | $49M | $47M | $66M | $71M | $70M | |
| Accum. Depreciation | · | $16M | $87M | $125M | $148M | $138M | $128M | $121M | $115M | $111M | $103M | $94M | |
| Goodwill | · | · | $0 | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | |
| Other Non-current Assets | $14M | $5M | $5M | $2M | $3M | $1M | $344.0K | $4M | $994.0K | $817.0K | $754.0K | $7M | |
| Total Assets | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Accounts Payable | $11M | $12M | $10M | $13M | $10M | $22M | $19M | $6M | $5M | $3M | $2M | $3M | |
| Accrued Liabilities | $22M | $30M | $22M | $37M | · | · | · | · | · | · | · | $6M | |
| Current Liabilities | $54M | $61M | $51M | $68M | $85M | $116M | $354M | $82M | $56M | $72M | $61M | $64M | |
| Capital Leases | $65M | $83M | $99M | $113M | $126M | $136M | $143M | $0 | · | $2M | $1M | $4M | |
| Other Non-current Liabilities | $9M | $7M | $5M | $8M | $4M | $9M | $768.0K | $10M | $6M | $7M | $10M | $15M | |
| Total Liabilities | $191M | $243M | $267M | $344M | $438M | $461M | $572M | $433M | $421M | $481M | $492M | $405M | |
| Common Stock | $2.0K | $1.0K | $19.0K | $19.0K | $19.0K | $18.0K | $17.0K | $17.0K | $15.0K | $15.0K | $13.0K | $13.0K | |
| Retained Earnings | $-3.76B | $-3.60B | $-3.48B | $-3.20B | $-2.83B | $-2.31B | $-1.86B | $-1.42B | $-2.12B | $-2.02B | $-1.87B | $-1.79B | |
| Treasury Stock | · | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $17.0K | $61.0K | $80.0K | $-7M | $-4M | $-2M | $-1M | $-6M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $90M | $61M | $131M | $367M | $680M | $1.08B | $1.41B | $1.72B | $88M | $88M | $6M | $36M | |
| Liabilities + Equity | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Shares Outstanding | 20,378,832 | 12,385,001 | 12,757,984 | 188,560,000 | 185,468,000 | 180,091,000 | 176,505,000 | 173,530,000 | 159,524,000 | 153,212,000 | 135,289,000 | 131,216,000 |
Cashflow 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $4M | $7M | $12M | $13M | $12M | $11M | $9M | $13M | $13M | $11M | $13M | |
| Stock-based Comp | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Deferred Tax | $64.0K | $-10.0K | $-140.0K | $3M | $-102.0K | $-36.0K | $-21.0K | $93.0K | $35.0K | $-115.0K | $-22.0K | $-31.0K | |
| Other Non-cash | · | $-61M | $77M | $49M | $98M | $119M | $101M | $28M | $4M | · | · | · | |
| Operating Cash Flow | $-209M | $-176M | $-193M | $-304M | $-413M | $-313M | $-329M | $718M | $-80M | $-117M | $-73M | $-142M | |
| CapEx | $171.0K | $1M | $865.0K | $6M | $15M | $7M | $26M | $14M | $10M | $6M | $11M | $10M | |
| Investing Cash Flow | $-1M | $143M | $140M | $366M | $203M | $496M | $207M | $-1.38B | $-29M | $-82M | · | · | |
| Stock Repurchased | $0 | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-3M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $181M | $42M | $30.0K | $2M | $36M | $-80M | $23M | $852M | $54M | $204M | · | · | |
| Net Change in Cash | $-29M | $9M | $-53M | $63M | $-174M | $103M | $-99M | $190M | $-55M | $4M | $43M | $-27M | |
| Taxes Paid | $-195.0K | $76.0K | $3M | $272.0K | $325.0K | $539.0K | $555.0K | $618.0K | $556.0K | $757.0K | $860.0K | $964.0K | |
| Free Cash Flow | $-209M | $-177M | $-193M | $-310M | $-428M | $-321M | $-355M | $704M | $-90M | $-123M | $-84M | · | |
| Levered FCF | · | · | · | $-310M | $-428M | $-327M | $-376M | $682M | $-112M | $-146M | $-103M | · |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% | -12.7% | · | |
| Net Margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% | -35.2% | · | |
| Pretax Margin | -297.3% | -121.1% | -306.5% | -396.5% | -513.5% | -290.3% | -383.9% | 57.2% | -31.2% | -92.3% | -35.0% | · | |
| EBITDA Margin | -253.7% | -102.7% | -284.8% | -395.4% | -425.0% | -269.8% | -374.3% | 58.4% | -15.3% | -68.2% | -12.7% | · | |
| ROA | -56.2% | -33.9% | -49.8% | -40.3% | -39.5% | -25.3% | -21.3% | 51.2% | -17.9% | -28.8% | -17.2% | · | |
| ROE | -500.1% | -217.0% | -190.2% | -94.5% | -70.7% | -39.5% | -30.4% | 38.9% | -109.9% | -324.7% | -379.7% | · | |
| ROIC | -155.8% | -172.9% | -201.2% | -103.5% | -65.7% | -39.5% | -31.4% | 40.0% | -68.3% | -128.8% | -459.7% | · |
Liquidität & Solvenz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 | 9.8 | 4.0 | 17.5 | 5.8 | 5.9 | 5.7 | · | |
| Quick Ratio | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 | 2.1 | 0.4 | 2.9 | 5.4 | 5.6 | 5.4 | · | |
| Interest Coverage | · | · | · | · | · | -62.1 | -20.6 | 31.9 | -2.7 | -5.0 | -1.6 | · |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.9 | 0.6 | 0.3 | 0.5 | · | |
| Inventory Turnover | · | 3.8 | 1.9 | 1.2 | 1.6 | 1.4 | 1.8 | 2.2 | 2.8 | 2.7 | 2.8 | · | |
| Receivables Turnover | · | 163.4 | 25.1 | 6.5 | 3.3 | 4.0 | 2.9 | 49.5 | 29.7 | 9.3 | 19.6 | · |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -43.9% | 9.2% | -2.1% | -9.7% | -33.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -15.7% | -1.1% | -16.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -18.4% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Net Income TTM | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| Market Cap | $862M | $2.59B | $1.61B | $6.39B | $37.59B | $45.92B | $57.16B | $85.56B | $142.90B | $28.20B | $34.19B | · | |
| P/E | -4.3 | -1.6 | -5.8 | -17.2 | -70.9 | -102.4 | -128.5 | 130.4 | -1444.8 | -167.3 | -414.3 | -516.7 | |
| P/S | 15.6 | 26.3 | 17.8 | 69.4 | 368.8 | 300.3 | 498.7 | 71.7 | 464.4 | 170.5 | 148.2 | · | |
| P/B | 9.6 | 42.7 | 12.3 | 17.4 | 55.3 | 42.6 | 40.7 | 49.8 | 1627.1 | 320.0 | 5318.8 | · | |
| P / Tangible Book | 9.6 | 42.7 | 12.3 | 22.0 | 62.3 | 45.9 | · | · | · | · | · | · | |
| P / Cash Flow | -4.1 | -14.7 | -8.3 | -21.0 | -91.1 | -146.6 | -173.9 | 119.1 | -1777.1 | -241.0 | -467.9 | · | |
| P / FCF | -4.1 | -14.6 | -8.3 | -20.6 | -87.9 | -143.3 | -161.0 | 121.5 | -1586.2 | -228.5 | -405.7 | · | |
| Earnings Yield | -23.0% | -62.2% | -17.3% | -5.8% | -1.4% | -0.98% | -0.78% | 0.77% | -0.07% | -0.60% | -0.24% | -0.19% |
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $11M | $22M | $12M | $11M | $10M | $29M | $24M | $23M | $22M | $24M | $24M | $20M | $22M | $22M | $24M | |
| Cost of Revenue | · | · | $0 | $0 | $0 | $0 | $8M | $4M | $10M | $9M | $7M | $12M | $7M | $7M | $6M | $5M | |
| R&D Expense | $39M | $36M | $30M | $27M | $30M | $30M | $29M | $35M | $30M | $27M | $30M | $24M | $30M | $30M | $35M | $34M | |
| SG&A Expense | $13M | $13M | $11M | $16M | $17M | $24M | $17M | $19M | $21M | $20M | $17M | $21M | $18M | $21M | $22M | $23M | |
| Operating Expenses | $52M | $50M | $49M | $43M | $47M | $55M | $15M | $58M | $73M | $57M | $57M | $69M | $71M | $156M | $74M | $78M | |
| Operating Income | $-42M | $-39M | $-28M | $-32M | $-36M | $-45M | $14M | $-34M | $-50M | $-35M | $-34M | $-45M | $-51M | $-135M | $-52M | $-54M | |
| Interest Income | $9M | $4M | $3M | $3M | $2M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $4M | · | · | |
| Other Non-op | $-100.0K | $-336.0K | $-44.0K | $-121.0K | $260.0K | $266.0K | $-135.0K | $-120.0K | $-36.0K | $-99.0K | $-6M | $-335.0K | $736.0K | $-301.0K | $-4M | $2M | |
| Pretax Income | $-40M | $-43M | $-43M | $-35M | $-39M | $-46M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-57M | $-59M | |
| Income Tax | $2.0K | $64.0K | $31.0K | $-33.0K | $-188.0K | $52.0K | $-259.0K | $9.0K | $46.0K | $-35.0K | $-29.0K | $-61.0K | $-47.0K | $-63.0K | $3M | $-155.0K | |
| Net Income | $-41M | $-45M | $-36M | $-36M | $-42M | $-51M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-60M | $-59M | |
| EPS (Basic) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| EPS (Diluted) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| Shares (Basic) | 33,054,865 | 24,736,066 | -227,086,936 | 18,946,559 | 14,087,307 | 14,063,402 | -208,906,454 | 13,949,851 | 13,921,378 | 194,746,000 | -378,936,000 | 190,406,000 | 189,656,000 | 188,875,000 | -373,151,000 | 187,641,000 | |
| Shares (Diluted) | 33,054,865 | 24,736,066 | -227,086,936 | 18,946,559 | 14,087,307 | 14,063,402 | -208,906,454 | 13,949,851 | 13,921,378 | 194,746,000 | -378,936,000 | 190,406,000 | 189,656,000 | 188,875,000 | -373,151,000 | 187,641,000 | |
| EBITDA | $-42M | $-39M | · | $-32M | $-36M | $-45M | · | $-34M | $-50M | $-35M | · | $-45M | $-51M | $-135M | · | $-54M |
Bilanz 23
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $150M | $15M | $41M | $43M | $39M | $44M | $30M | $28M | $49M | $35M | $65M | $51M | $77M | $88M | $106M | |
| Receivables | · | · | · | · | · | · | · | $0 | $1M | $4M | $1M | $2M | $1M | $3M | $6M | $12M | |
| Inventory | · | · | $0 | · | · | · | $0 | $0 | $14M | $16M | $16M | $15M | $21M | $20M | $19M | $19M | |
| Other Current Assets | $55M | $20M | $21M | $11M | $11M | $11M | $6M | $9M | $8M | $11M | $10M | $9M | $10M | $11M | $16M | $23M | |
| Current Assets | $739M | $589M | $266M | $281M | $187M | $230M | $261M | $286M | $295M | $320M | $331M | $399M | $441M | $491M | $546M | $599M | |
| PP&E (Net) | · | · | $2M | $3M | $3M | $3M | $3M | $4M | $15M | $17M | $19M | $20M | $23M | $27M | $32M | $37M | |
| Accum. Depreciation | · | · | · | · | · | · | · | $16M | $88M | · | $87M | $88M | $108M | $111M | $125M | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $77M | $77M | |
| Other Non-current Assets | $17M | $11M | $6M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $2M | $1M | $2M | $2M | |
| Total Assets | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Accounts Payable | $25M | $10M | $11M | $16M | $14M | $18M | $12M | $9M | $6M | $9M | $10M | $3M | $3M | $4M | $13M | $5M | |
| Accrued Liabilities | $23M | $25M | $22M | $29M | $35M | $31M | $30M | $32M | $30M | $24M | $22M | $30M | $29M | $37M | $37M | · | |
| Current Liabilities | $71M | $58M | $54M | $66M | $71M | $71M | $61M | $68M | $57M | $52M | $51M | $52M | $51M | $60M | $68M | $84M | |
| Capital Leases | $56M | $61M | $65M | $70M | $74M | $78M | $83M | $87M | $91M | $95M | $99M | $102M | $106M | $109M | $113M | $116M | |
| Other Non-current Liabilities | $8M | $8M | $9M | $5M | $6M | $7M | $7M | $7M | $8M | $4M | $5M | $5M | $5M | $6M | $8M | $3M | |
| Total Liabilities | $192M | $187M | $191M | $216M | $232M | $243M | $243M | $259M | $264M | $269M | $267M | $283M | $297M | $321M | $344M | $369M | |
| Common Stock | $3.0K | $3.0K | $2.0K | $2.0K | $1.0K | $19.0K | $1.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | |
| Retained Earnings | $-3.85B | $-3.81B | $-3.76B | $-3.72B | $-3.69B | $-3.65B | $-3.60B | $-3.60B | $-3.57B | $-3.51B | $-3.48B | $-3.44B | $-3.39B | $-3.34B | $-3.20B | $-3.14B | |
| Treasury Stock | · | · | · | $0 | $3M | $3M | $3M | $3M | $3M | $3M | · | · | · | · | · | · | |
| AOCI | $-2M | $-1M | $17.0K | $56.0K | $-14.0K | $39.0K | $61.0K | $355.0K | $-494.0K | $-403.0K | $80.0K | $-6M | $-6M | $-6M | $-7M | $-8M | |
| Stockholders' Equity | $903M | $576M | $90M | $85M | $-24M | $14M | $61M | $49M | $80M | $127M | $131M | $159M | $197M | $241M | $367M | $412M | |
| Liabilities + Equity | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Shares Outstanding | 20,378,832 | 20,378,832 | 20,378,832 | 19,652,513 | 12,457,252 | 186,103,000 | 12,385,001 | 184,458,000 | 184,061,000 | 183,624,000 | 191,384,000 | 190,771,000 | 190,119,000 | 189,235,000 | 188,560,000 | 187,954,000 |
Cashflow 12
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $156.0K | $151.0K | $190.0K | $196.0K | $214.0K | $426.0K | $332.0K | $993.0K | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $2.0K | $-31.0K | $57.0K | $-38.0K | $2M | $-15.0K | $-27.0K | $-2M | $3M | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Operating Cash Flow | $-76M | $-44M | $-65M | $-49M | $-46M | $-49M | $-46M | $-44M | $-38M | $-48M | $-47M | $-42M | $-52M | $-52M | $-58M | $-83M | |
| CapEx | $94.0K | $18.0K | $18.0K | $114.0K | $37.0K | $2.0K | $459.0K | $666.0K | $186.0K | $157.0K | $237.0K | $33.0K | $162.0K | $433.0K | $512.0K | $181.0K | |
| Investing Cash Flow | $-399M | $-351M | $372.0K | $-95M | $50M | $44M | $60M | $46M | $17M | $19M | $17M | $56M | $25M | $41M | $40M | $111M | |
| Stock Repurchased | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $-3M | · | · | · | · | · | · | |
| Financing Cash Flow | $365M | $530M | $39M | $142M | $211.0K | $7.0K | $83.0K | $13.0K | $19.0K | $42M | $12.0K | $0 | $18.0K | $0 | $103.0K | $0 | |
| Net Change in Cash | $-110M | $134M | $-26M | $-2M | $4M | $-5M | $14M | $2M | $-21M | $13M | $-30M | $14M | $-26M | $-11M | $-18M | $28M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | $272.0K | $-85.0K | |
| Free Cash Flow | · | $-44M | · | · | · | $-49M | · | · | · | $-48M | · | · | · | $-52M | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| Net Margin | -401.0% | -413.4% | · | -301.3% | -372.2% | -486.4% | · | -153.6% | -222.9% | -170.1% | · | -189.8% | -249.4% | -634.5% | · | -249.9% | |
| Pretax Margin | -397.8% | -396.7% | · | -297.0% | -352.5% | -443.3% | · | -153.6% | -222.7% | -170.2% | · | -190.1% | -249.6% | -634.8% | · | -250.6% | |
| EBITDA Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| ROA | -6.2% | -8.8% | · | -11.7% | -15.1% | -15.6% | · | -9.9% | -12.5% | -7.7% | · | -7.5% | -7.5% | -17.3% | · | -5.7% | |
| ROE | -9.2% | -15.2% | · | -53.0% | -150.0% | -72.5% | · | -35.6% | -37.9% | -20.0% | · | -16.0% | -15.6% | -32.3% | · | -9.7% | |
| ROIC | -4.7% | -6.8% | · | -37.2% | 148.9% | -324.5% | · | -70.3% | -62.5% | -27.9% | · | -28.1% | -25.7% | -55.9% | · | -13.1% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.4 | 10.2 | · | 4.2 | 2.6 | 3.2 | · | 4.2 | 5.1 | 6.1 | · | 7.7 | 8.7 | 8.2 | · | 7.1 | |
| Quick Ratio | 0.6 | 2.6 | · | 0.6 | 0.6 | 0.5 | · | 0.4 | 0.5 | 1.0 | · | 1.3 | 1.0 | 1.3 | · | 1.4 |
Effizienz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.6 | 0.6 | 0.5 | · | 0.7 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | 21.9 | 18.6 | 6.5 | · | 3.5 | 3.6 | 1.3 | · | 1.2 |
Bewertung (TTM) 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $44M | $44M | · | $58M | $69M | $80M | · | $93M | $90M | $88M | · | $90M | $87M | $92M | · | $95M | |
| Net Income TTM | $-163M | $-173M | · | $-165M | $-182M | $-177M | · | $-172M | $-186M | $-271M | · | $-293M | $-406M | $-446M | · | $-454M | |
| Market Cap | $1.42B | $1.47B | · | $1.12B | $322M | $1.90B | · | $3.60B | $3.42B | $2.56B | · | $1.72B | $1.65B | $1.99B | · | $9.02B | |
| P/E | -8.9 | -7.0 | · | -7.4 | -2.7 | -1.5 | · | -2.8 | -4.2 | -9.8 | · | -5.8 | -4.0 | -4.4 | · | -0.1 | |
| P/S | 32.4 | 33.1 | · | 19.4 | 4.6 | 23.8 | · | 38.5 | 38.1 | 29.1 | · | 19.1 | 18.9 | 21.7 | · | 94.9 | |
| P/B | 1.6 | 2.5 | · | 13.1 | -13.3 | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 21.9 | |
| P / Tangible Book | 1.6 | 2.5 | · | 13.1 | · | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 26.9 | |
| P / Cash Flow | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.5 | · | · | · | -38.3 | · | · | |
| P / FCF | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.3 | · | · | · | -38.0 | · | · | |
| Earnings Yield | -11.3% | -14.3% | · | -13.6% | -37.2% | -67.2% | · | -35.1% | -24.0% | -10.2% | · | -17.2% | -24.8% | -22.7% | · | -1649.3% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $55M | $98M | $90M | $92M | $102M |
| Betriebsgewinnmarge % | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% |
| Nettoergebnis | $-164M | $-119M | $-276M | $-368M | $-524M |
| Verwässerte EPS | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 |
| Quick Ratio | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-209M | $-177M | $-193M | $-310M | $-428M |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 269 Einreicher · $2.1B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 88 (+20 vs. Vorquartal) | 41 (+9 vs. Vorquartal) | 91 (+21 vs. Vorquartal) | 48 (-8 vs. Vorquartal) | +8.5M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Two Seas Capital LP | $215.868.856 | 3.092.234 | 10,35% | Aktien |
| FMR LLC | $192.088.149 | 2.751.585 | 9,21% | Aktien |
| BVF INC/IL | $166.920.946 | 2.391.075 | 8,00% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $104.495.029 | 1.496.849 | 5,01% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $83.911.899 | 1.202.004 | 4,02% | Aktien |
| Vestal Point Capital, LP | $69.810.000 | 1.000.000 | 3,35% | Aktien |
| STATE STREET CORP | $63.504.691 | 909.679 | 3,04% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57.502.497 | 823.700 | 2,76% | Kaufoption |
| Prosight Management, LP | $56.546.100 | 810.000 | 2,71% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $52.759.799 | 755.586 | 2,53% | Aktien |
| ARMISTICE CAPITAL, LLC | $50.542.440 | 724.000 | 2,42% | Aktien |
| GILDER GAGNON HOWE & CO LLC | $41.946.944 | 600.873 | 2,01% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $33.377.557 | 478.120 | 1,60% | Aktien |
| BRAIDWELL LP | $33.063.203 | 473.617 | 1,59% | Aktien |
| Sofinnova Investments, Inc. | $32.933.775 | 471.763 | 1,58% | Aktien |
| Woodline Partners LP | $32.871.784 | 470.875 | 1,58% | Aktien |
| ORBIMED ADVISORS LLC | $32.485.804 | 465.346 | 1,56% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $27.540.045 | 394.500 | 1,32% | Verkaufsoption |
| EMERALD ADVISERS, LLC | $27.236.930 | 390.158 | 1,31% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $24.331.577 | 348.540 | 1,17% | Aktien |
| DAFNA Capital Management LLC | $22.226.108 | 318.380 | 1,07% | Aktien |
| Deep Track Capital, LP | $20.943.000 | 300.000 | 1,00% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19.893.826 | 284.971 | 0,95% | Aktien |
| 22NW, LP | $19.624.638 | 281.115 | 0,94% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.475.384 | 278.977 | 0,93% | Aktien |
| PRIMECAP MANAGEMENT CO/CA/ | $19.047.658 | 272.850 | 0,91% | Aktien |
| Nearwater Capital Markets, Ltd | $18.255.315 | 261.500 | 0,88% | Aktien |
| BARCLAYS PLC | $17.968.815 | 257.396 | 0,86% | Aktien |
| EMERALD MUTUAL FUND ADVISERS TRUST | $17.842.528 | 255.587 | 0,86% | Aktien |
| ADAR1 Capital Management, LLC | $17.046.485 | 244.184 | 0,82% | Aktien |
| Creek Drive Management Group LLC | $16.963.830 | 243.000 | 0,81% | Aktien |
| SEVEN GRAND MANAGERS, LLC | $16.754.400 | 240.000 | 0,80% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $16.724.731 | 239.575 | 0,80% | Aktien |
| NORGES BANK | $15.030.093 | 215.300 | 0,72% | Aktien |
| Bronte Capital Management Pty Ltd. | $13.852.678 | 198.434 | 0,66% | Aktien |
| TWO SIGMA ADVISERS, LP | $13.039.744 | 308.414 | 0,63% | Aktien |
| CITADEL ADVISORS LLC | $12.251.655 | 175.500 | 0,59% | Verkaufsoption |
| GREAT POINT PARTNERS LLC | $12.216.750 | 175.000 | 0,59% | Aktien |
| Caption Management, LLC | $11.944.491 | 171.100 | 0,57% | Kaufoption |
| MILLENNIUM MANAGEMENT LLC | $11.867.700 | 170.000 | 0,57% | Kaufoption |
| CITADEL ADVISORS LLC | $11.434.878 | 163.800 | 0,55% | Kaufoption |
| AMERIPRISE FINANCIAL INC | $11.050.085 | 158.288 | 0,53% | Aktien |
| Quinn Opportunity Partners LLC | $10.686.236 | 153.076 | 0,51% | Aktien |
| GOLDMAN SACHS GROUP INC | $10.011.801 | 143.415 | 0,48% | Aktien |
| Rhenman & Partners Asset Management AB | $9.860.662 | 141.250 | 0,47% | Aktien |
| Qube Research & Technologies Ltd | $9.111.671 | 130.521 | 0,44% | Aktien |
| LMR Partners LLP | $9.075.300 | 130.000 | 0,44% | Verkaufsoption |
| Soleus Capital Management, L.P. | $8.960.951 | 128.362 | 0,43% | Aktien |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $8.570.364 | 122.767 | 0,41% | Aktien |
| Stonepine Capital Management, LLC | $8.422.856 | 120.654 | 0,40% | Aktien |
| SummitTX Capital, L.P. | $7.883.923 | 112.934 | 0,38% | Aktien |
| APEIRON CAPITAL Ltd | $7.429.948 | 106.431 | 0,36% | Aktien |
| CITIGROUP INC | $7.034.824 | 100.771 | 0,34% | Aktien |
| ING GROEP NV | $6.981.000 | 100.000 | 0,33% | Aktien |
| LMR Partners LLP | $6.981.000 | 100.000 | 0,33% | Aktien |
| Susquehanna Portfolio Strategies, LLC | $6.685.704 | 95.770 | 0,32% | Aktien |
| Militia Capital Management LLC | $6.282.900 | 90.000 | 0,30% | Aktien |
| ACT CAPITAL MANAGEMENT, LLC | $6.234.033 | 89.300 | 0,30% | Aktien |
| Tetragon Partners GP Ltd | $6.073.191 | 86.996 | 0,29% | Aktien |
| READYSTATE ASSET MANAGEMENT LP | $5.941.529 | 85.110 | 0,28% | Aktien |
| Birchview Capital, LP | $5.654.610 | 81.000 | 0,27% | Aktien |
| BlackRock, Inc. | $5.444.412 | 77.989 | 0,26% | Aktien |
| GROUP ONE TRADING LLC | $4.912.600 | 70.371 | 0,24% | Aktien |
| ALGERT GLOBAL LLC | $4.686.345 | 67.130 | 0,22% | Aktien |
| Moody Aldrich Partners LLC | $4.477.264 | 64.135 | 0,21% | Aktien |
| WOLVERINE TRADING, LLC | $4.330.620 | 73.500 | 0,21% | Verkaufsoption |
| Swiss National Bank | $4.300.296 | 61.600 | 0,21% | Aktien |
| F/m Investments LLC | $4.229.439 | 60.585 | 0,20% | Aktien |
| BANK OF AMERICA CORP /DE/ | $4.227.764 | 60.561 | 0,20% | Aktien |
| ExodusPoint Capital Management, LP | $4.084.374 | 58.507 | 0,20% | Aktien |
| Trexquant Investment LP | $3.956.831 | 56.680 | 0,19% | Aktien |
| K2 PRINCIPAL FUND, L.P. | $3.522.962 | 50.465 | 0,17% | Aktien |
| WOLVERINE TRADING, LLC | $3.403.101 | 57.758 | 0,16% | Aktien |
| RHUMBLINE ADVISERS | $3.008.381 | 43.094 | 0,14% | Aktien |
| MORGAN STANLEY | $2.943.050 | 42.158 | 0,14% | Aktien |
| Voleon Capital Management LP | $2.850.901 | 40.838 | 0,14% | Aktien |
| Anson Funds Management LP | $2.829.748 | 40.535 | 0,14% | Aktien |
| Atom Investors LP | $2.828.631 | 40.519 | 0,14% | Aktien |
| WOLVERINE TRADING, LLC | $2.792.808 | 47.400 | 0,13% | Kaufoption |
| Burkehill Global Management, LP | $2.792.400 | 40.000 | 0,13% | Aktien |
| NOMURA HOLDINGS INC | $2.792.400 | 40.000 | 0,13% | Verkaufsoption |
| IRIDIAN ASSET MANAGEMENT LLC/CT | $2.708.768 | 38.802 | 0,13% | Aktien |
| NOMURA HOLDINGS INC | $2.698.645 | 38.657 | 0,13% | Aktien |
| Jefferies Financial Group Inc. | $2.664.299 | 38.165 | 0,13% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $2.590.200 | 36.000 | 0,12% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $2.575.780 | 36.897 | 0,12% | Aktien |
| ALPS ADVISORS INC | $2.386.664 | 34.188 | 0,11% | Aktien |
| FRED ALGER MANAGEMENT, LLC | $2.350.712 | 33.673 | 0,11% | Aktien |
| TUDOR INVESTMENT CORP ET AL | $2.345.616 | 33.600 | 0,11% | Kaufoption |
| Bank of New York Mellon Corp | $2.306.522 | 33.040 | 0,11% | Aktien |
| Ghisallo Capital Management LLC | $2.233.920 | 32.000 | 0,11% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2.063.670 | 28.682 | 0,10% | Aktien |
| Blackstone Inc. | $2.002.011 | 28.678 | 0,10% | Aktien |
| KVP Capital Advisors, LP | $1.877.889 | 26.900 | 0,09% | Aktien |
| Ishara Investments LP | $1.860.437 | 26.650 | 0,09% | Aktien |
| Erste Asset Management GmbH | $1.830.920 | 28.000 | 0,09% | Aktien |
| Caption Management, LLC | $1.822.041 | 26.100 | 0,09% | Verkaufsoption |
| WINTON GROUP Ltd | $1.808.079 | 25.900 | 0,09% | Aktien |
| K2 PRINCIPAL FUND, L.P. | $1.745.250 | 25.000 | 0,08% | Kaufoption |
| Empowered Funds, LLC | $1.636.416 | 23.441 | 0,08% | Aktien |
Unternehmensinsider 40 Insider · 20 Führungskräfte · 18 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Howard W Robin | President & CEO | 24. Juli 2026 A | 55.045 | 0 | 20 | $-2.224.055 |
| Jillian B. Thomsen | Chief Financial Officer | 16. Februar 2023 S | 313.497 | 0 | 0 | $0 |
| Gil M Labrucherie | SVP, COO & CFO | 16. Mai 2022 S | 312.905 | 0 | 0 | $0 |
| Timothy Harkness | SVP & Chief Financial Officer | 23. August 2007 A | — | 0 | 0 | $0 |
| Louis Drapeau | Sr. VP Finance, CFO | 14. Mai 2007 A | 6.000 | 0 | 0 | $0 |
| Milton J Harris | President of Nektar AL | 4. März 2004 S | 743.904 | 0 | 0 | $0 |
| John Nicholson | SVP & Chief Operating Officer | 16. August 2019 S | 162.759 | 0 | 0 | $0 |
| Bharat M Chowrira | Chief Operating Officer | 1. Februar 2010 A | — | 0 | 0 | $0 |
| Jonathan Zalevsky | Chief R&D Officer | 24. Juli 2026 A | 9.756 | 0 | 12 | $-1.052.364 |
| Mark Andrew Wilson | Chief Legal Officer | 21. November 2025 A | 21.585 | 0 | 2 | $-52.171 |
| John Northcott | SVP & Chief Commercial Officer | 16. Mai 2022 S | 223.210 | 0 | 0 | $0 |
| Stephen K Doberstein | SVP & Chief Scientific Officer | 5. September 2019 P | 107.668 | 0 | 0 | $0 |
| Maninder Hora | SVP Pharma Dev & Mfg Ops | 16. Mai 2019 S | 94.694 | 0 | 0 | $0 |
| Ivan P. Gergel | SVP & Chief Medical Officer | 15. November 2017 A | 56.553 | 0 | 0 | $0 |
| Robert Medve | SVP & Chief Medical Officer | 5. Februar 2014 A | — | 0 | 0 | $0 |
| Rinko Ghosh | Chief Business Officer | 6. Februar 2013 A | 9.753 | 0 | 0 | $0 |
| Randall W Moreadith | SVP Drug Development | 23. Februar 2009 A | — | 0 | 0 | $0 |
| John Stuart Patton | Chief Scientific Officer | 14. November 2008 M | 313.880 | 0 | 0 | $0 |
| Nevan C Elam | SVP & Head of Pulmonary Bus | 25. Februar 2008 A | 1.400 | 0 | 0 | $0 |
| David Johnston | SVP, Research & Development | 14. Mai 2007 D | 6.600 | 0 | 0 | $0 |
| Diana Brainard | Direktor | 30. September 2025 A | 28.560 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | Direktor | 30. September 2025 A | 34.153 | 0 | 0 | $0 |
| Robert Chess | Direktor | 30. September 2025 A | 255.273 | 0 | 0 | $0 |
| Scott R Greer | Direktor | 30. September 2025 A | 303.574 | 0 | 0 | $0 |
| Roy A Whitfield | Direktor | 30. September 2025 A | 216.250 | 0 | 0 | $0 |
| Myriam Curet | Direktor | 19. September 2023 A | 27.418 | 0 | 0 | $0 |
| Karin Eastham | Direktor | 16. September 2022 A | 23.233 | 0 | 0 | $0 |
| Lutz Lingnau | Direktor | 22. September 2020 A | 35.800 | 0 | 0 | $0 |
| Christopher A Kuebler | Direktor | 27. September 2018 A | 45.250 | 0 | 0 | $0 |
| Dennis L Winger | Direktor | 21. August 2018 M | 42.750 | 0 | 0 | $0 |
| Joseph J Krivulka | Direktor | 19. September 2017 A | 82.000 | 0 | 0 | $0 |
| Susan Wang | Direktor | 20. November 2015 M | 20.000 | 0 | 0 | $0 |
| BROWN MICHAEL A/CA | Direktor | 15. September 2009 A | 10.000 | 0 | 0 | $0 |
| Hoyoung Huh | Direktor | 2. Dezember 2008 A | — | 0 | 0 | $0 |
| Irwin Lerner | Direktor | 2. Dezember 2008 A | 10.000 | 0 | 0 | $0 |
| James B Glavin | Direktor | 4. September 2003 A | — | 0 | 0 | $0 |
| Masuoka K. Lorianne | — | 8. Februar 2011 A | — | 0 | 0 | $0 |
| Ajit Gill | President & CEO | 23. März 2006 S | 87.991 | 0 | 0 | $0 |
| Ajay Bansal | — | 10. März 2006 S | 5.166 | 0 | 0 | $0 |
| Melvin Perelman | — | 2. September 2004 A | — | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 1 Beteiligung
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Nektar Therapeutics ( | 22. August 2005 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 28 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,14% | 50.876 NS | 31. Mai 2026 | N-PORT |
| SPIT · RBB Fund, Inc. | 3,11% | 10.455 NS | 30. April 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,55% | 2.353 NS | 30. April 2026 | N-PORT |
| BBC · ETFis Series Trust I | 1,15% | 5.045 NS | 30. April 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,58% | 1.726 SH | 8. August 2026 | Täglich |
| IHE · iShares Trust | 0,55% | 120.730 SH | 8. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 59.612 SH | 8. August 2026 | Täglich |
| IWO · iShares Trust | 0,14% | 278.376 SH | 8. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,13% | 33.135 SH | 8. August 2026 | Täglich |
| TMFX · RBB Fund, Inc. | 0,09% | 455 NS | 31. Mai 2026 | N-PORT |
| IWM · iShares Trust | 0,08% | 877.973 SH | 8. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 198.365 SH | 8. August 2026 | Täglich |
| ISCV · iShares Trust | 0,07% | 6.414 SH | 8. August 2026 | Täglich |
| SCHA · SCHWAB STRATEGIC TRUST | 0,04% | 151.830 NS | 31. Mai 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 11.131 NS | 30. April 2026 | N-PORT |
| ISCB · iShares Trust | 0,03% | 1.294 SH | 8. August 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 387.471 SH | 8. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,03% | 92.340 SH | 8. August 2026 | Täglich |
| WSML · iShares Trust | 0,02% | 1.887 SH | 8. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 3.096 SH | 8. August 2026 | Täglich |
| IWN · iShares Trust | 0,02% | 32.466 SH | 8. August 2026 | Täglich |
| ONEQ · Fidelity Commonwealth Trust | 0,00% | 6.903 NS | 31. Mai 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 48.124 SH | 8. August 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 9.139 SH | 8. August 2026 | Täglich |
| TILT · FlexShares Trust | 0,00% | 770 NS | 30. April 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 18.540 NS | 31. Mai 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.075.430 SH | 8. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.837 SH | 8. August 2026 | Täglich |